Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Lutetium-177-PSMA-617 Radioligand Therapy in Oligo-metastatic Hormone Sensitive Prostate Cancer.

NCT04443062 is registered in ClinicalTrials.gov with Radboud University Medical Center as lead sponsor.

NCT NCT04443062
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04443062 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Lutetium-177-PSMA-617 Radioligand Therapy in Oligo-metastatic Hormone Sensitive Prostate Cancer.
Lead sponsor
Radboud University Medical Center
Phase
Phase 2
Overall status
Completed
Start date
July 20, 2020
Completion date
January 1, 2026
Enrollment
58 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer